Navigation Links
Research Offers Promise for Cirrhosis Treatment
Date:12/27/2007

Protein stops liver scarring in mice, study finds

THURSDAY, Dec. 27 (HealthDay News) -- New findings about the inner workings of cells may be bringing scientists one step closer to reversing the scarring of the liver known as cirrhosis.

Currently, the best treatment for advanced cirrhosis is a liver transplant, an option that's often not available. But newly released research with mice suggests that a drug-based strategy could reprogram cells and make it "feasible to treat it [cirrhosis] and prevent it without a transplant," said study lead author Martina Buck, an assistant professor of medicine at the University of California, San Diego.

There's no guarantee, however, that the treatment will work in humans. And Buck said it could take at least five to 10 years for a drug to reach the market if a pharmaceutical company became interested in pursuing it.

But the research might also lead to new treatments for other conditions that lead to excess tissue scarring, such as viral hepatitis, fatty liver disease, pulmonary fibrosis, scleroderma and burns, the study authors said.

At issue is scarring in the liver, an organ that filters out toxins and breaks down medications. The scarring is a "natural healing process," Buck said, but overuse of alcohol and diseases like hepatitis can make the scarring become chronic and lead to major health problems like cancer.

In the new study, Buck and her colleagues focused on liver cells that transform into scar tissue when activated. They used mice with severe liver fibrosis that was brought about by chronic exposure to a toxin known to cause liver damage. Next, they genetically engineered mice to activate a protein that provides protection against scarring.

The researchers found that the protein seemed to protect the mice from scarring, and "if you wait until [a mouse] has cirrhosis before you treat him, he will actually regress. It's not just a preventive thing. It's an actual treatment," Buck said.

The study was published Dec. 26 in the journal Public Library of Science Online.

Research into the workings of liver cells in people suggests that the treatment might also work in humans, Buck said. Potentially, the treatment could be converted into a drug that could be given orally or intravenously, she said.

Dr. Scott Friedman, chief of the Division of Liver Diseases at Mount Sinai School of Medicine in New York City, said that while the study is useful, it's "not a major breakthrough" considering the many research projects in a similar stage of development.

Still, he said, it "builds on 20 years of very exciting research" that looks at how cells create scarring in the liver.

More information

Learn more about cirrhosis from the U.S. National Institutes of Health.



SOURCES: Martina Buck, Ph.D., assistant professor of medicine, University of California, San Diego; Scott L. Friedman, M.D., Fishberg Professor of Medicine, and chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York City; Dec. 26, 2007, Public Library of Science Online


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:5/5/2016)... ... ... Vitenas Cosmetic Surgery has been named as one of the eight recipients ... and the Academy of Architecture for Health. The building, brainchild of founder Paul Vitenas, ... in October of 2014. , The prestigious Healthcare Design Awards are ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun Health registered nurse ... organization’s successful Care Transitions program at the 9th Annual Orthopedic and ... Costs in the Post-Acute Environment Through Effective Transitions of Care.” , Major changes ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy joints ... the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point ... arthritis. , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... and winners Tuesday evening, May 3, at the 2016 ISE® Central Executive Forum ... Pettigrew, Vice President and Chief Security Officer of HMS, was selected as the ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute lymphocytic Leukemia Market ... to their offering.       (Logo: ... Acute Lymphocytic Leukemia Market and Competitive Landscape ... Lymphocytic Leukemia pipeline products, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its ... http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... watching a film or TV show in high definition, you may not be familiar with ...  is a renowned authorized reseller of the medical industry,s top brands as well as a ... ... ... Although initially introduced ...
Breaking Medicine Technology: